glp-1 for alcohol use disorder Possible mechanisms by which may reduce consumption. (A) The Growing Scientific Case for

Today, it is part of a growing cohort of brands targeting the GLP-1 food space with prebiotic fibre

While this isn't a direct rejection of the drug's potential, it does mean a delay for patients and families hoping for a higher-dose option

Many patients describe feeling controlled by food rather than making autonomous choices about eating

Discontinuation rates in trials range from 2040% due to tolerability issues, making this medication challenging for sensitive individuals

They are prescribed to individuals who struggle with obesity or are overweight with at least one weight-related condition, such as hypertension, high cholesterol, or Type 2 diabetes

Gimeno Orna JA, Ortez Toro JJ, Peteiro Miranda CM